UDP-Glucose Dehydrogenase (UGDH) in Clinical Oncology and Cancer Biology | Oncotarget

Posted by

Oncotarget

Oncotarget published this trending review on September 28, 2023 in Volume 14, entitled, “UDP-glucose dehydrogenase (UGDH) in clinical oncology and cancer biology" by researchers from the Department of Internal Medicine, Johns Hopkins Hospital, Baltimore, MD; Department of Neurosurgery, Duke University Medical Center, Durham, NC; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC; Department of Neurosurgery, Associated with Duke University Medical Center, Durham, NC; Department of Epidemiology and Clinical Research, Stanford University, Stanford, CA; Department of Neurosurgery, Duke Center for Brain and Spine Metastasis and Duke Cancer Institute, Durham, NC. DOI - https://doi.org/10.18632/oncotarget.28514 Correspondence to - C. Rory Goodwin - rory.goodwin@duke.edu Abstract UDP-glucose-6-dehydrogenase (UGDH) is a cytosolic, hexameric enzyme that converts UDP-glucose to UDP-glucuronic acid (UDP-GlcUA), a key reaction in hormone and xenobiotic metabolism and in the production of extracellular matrix precursors. In this review, we classify UGDH as a molecular indicator of tumor progression in multiple cancer types, describe its involvement in key canonical cancer signaling pathways, and identify methods to inhibit UGDH, its substrates, and its downstream products. As such, we position UGDH as an enzyme to be exploited as a potential prognostication marker in oncology and a therapeutic target in cancer biology. Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28514 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, UDP-6 glucose dehydrogenase, UGDH, oncology, cancer biology About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957